Cashu
Larimar Therapeutics (LRMR) Under Legal Investigation for Alleged Misleading Statements on Clinical Trials
4 months ago
Stocks
Health Care
lrmr
Larimar Therapeutics
NASDAQ: LRMR
+2.39 (+64.63%)
6.075
USD
At close at Feb 25, 20:38 UTC
Overview
Loading chart...
Key Stats
Market Cap
315.83M
Dividend Yield
0.00%
P/E Ratio
-2.39
EPS
-1.31
Revenue
-
Avg. Volume
14.75M
About
What does LRMR do?
Larimar Therapeutics, based in Bala Cynwyd, Pennsylvania, focuses on developing novel therapeutics for mitochondrial disorders and Friedreich's ataxia using its cell penetrating peptide technology. Its lead candidate, nomlabofusp, aims to deliver essential protein frataxin to mitochondria for treating this rare disease.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.